semaglutide cancer Frontiers A growing body of research

Goncalves MO et al

The following summarizes the manufacturers recommended starting doses for the product: For patients nave to basal insulin or a GLP-1 RA: Start at 10 units subcutaneously once daily without regard to meals

You should contact your GP or diabetes care team if: Cold sensitivity is severe, persistent, or progressively worsening You experience cold intolerance accompanied by other symptoms such as extreme fatigue, constipation, dry skin, hair loss, or unexplained weight gain You develop symptoms suggestive of hypothyroidism (underactive thyroid), which can cause cold sensitivity (note that while GLP-1 receptor agonists have been associated with C-cell tumours in rodent studies, there is no established link to hypothyroidism in humans) You notice signs of anaemia, such as pallor, breathlessness, or palpitations, which can cause cold sensitivity Cold hands or feet are accompanied by colour changes (white, blue, or red), pain, or numbness, which may indicate circulatory problems You experience unexplained fever, chills, or rigors, which could suggest infection You have symptoms of hypoglycaemia (low blood sugar) such as shakiness, sweating, or confusion, especially if you also take insulin or sulfonylureas NICE guidance (NG28) recommends regular monitoring of patients on GLP-1 receptor agonists, including assessment of glycaemic control, weight, and tolerability

In the same study, Trulicity and Ozempic were also compared for weight loss in people with type 2 diabetes

On February 7, HIMS stopped offering its compounded oral semaglutide pill, just two days after launch

it also has a hypercoagulatory effect by binding to plasma proteins